Analysis and Commentary STEVEN GROSSMAN 2/3/23 Analysis and Commentary STEVEN GROSSMAN 2/3/23 The President’s FY24 Budget Request and the Appropriations Cycle Read More Advocacy at a Glance STEVEN GROSSMAN 2/3/23 Advocacy at a Glance STEVEN GROSSMAN 2/3/23 FDA Proposes to Reorganize Food Safety; More Details Coming Read More Analysis and Commentary STEVEN GROSSMAN 1/27/23 Analysis and Commentary STEVEN GROSSMAN 1/27/23 What the Alliance Told the Commissioner About Food Safety Read More Advocacy at a Glance STEVEN GROSSMAN 1/27/23 Advocacy at a Glance STEVEN GROSSMAN 1/27/23 Upcoming: Fireside Chat with Dr. Robert Califf Read More Analysis and Commentary STEVEN GROSSMAN 1/20/23 Analysis and Commentary STEVEN GROSSMAN 1/20/23 What is the Latest in FDA Policy, Legislation, and International Affairs? Read More Advocacy at a Glance STEVEN GROSSMAN 1/20/23 Advocacy at a Glance STEVEN GROSSMAN 1/20/23 Harris to Chair House Ag/FDA Subcommittee Read More Analysis and Commentary STEVEN GROSSMAN 1/13/23 Analysis and Commentary STEVEN GROSSMAN 1/13/23 A Separate Food Agency? Read More Advocacy at a Glance STEVEN GROSSMAN 1/13/23 Advocacy at a Glance STEVEN GROSSMAN 1/13/23 Appropriations, Debt Ceiling Uncertain Read More Analysis and Commentary STEVEN GROSSMAN 1/6/23 Analysis and Commentary STEVEN GROSSMAN 1/6/23 The Alliance Believes in FDA Exceptionalism, You Should Too. Read More Advocacy at a Glance STEVEN GROSSMAN 1/6/23 Advocacy at a Glance STEVEN GROSSMAN 1/6/23 Battle for Speaker has Implications for Appropriations Read More Advocacy at a Glance STEVEN GROSSMAN 12/23/22 Advocacy at a Glance STEVEN GROSSMAN 12/23/22 Alliance thanks Appropriators for FY23’ Plans for FY24 Read More Analysis and Commentary STEVEN GROSSMAN 12/23/22 Analysis and Commentary STEVEN GROSSMAN 12/23/22 Q&A on FDA’s FY23 Appropriation (let us know if you have other questions) Read More Analysis and Commentary STEVEN GROSSMAN 12/16/22 Analysis and Commentary STEVEN GROSSMAN 12/16/22 FDA Benefits If You Join the Alliance for a Stronger FDA Read More Advocacy at a Glance STEVEN GROSSMAN 12/16/22 Advocacy at a Glance STEVEN GROSSMAN 12/16/22 One Week CR; FY23 Approps Looks Hopeful; Elections Complete Read More Analysis and Commentary STEVEN GROSSMAN 12/9/22 Analysis and Commentary STEVEN GROSSMAN 12/9/22 Webinar with Valerie Jensen, Associate Director of FDA’s Drug Shortage Staff Read More Advocacy at a Glance STEVEN GROSSMAN 12/9/22 Advocacy at a Glance STEVEN GROSSMAN 12/9/22 Warnock Reelected; FY23 Approps at an Impasse; Response to Reagan-Udall Foundation’s Report Read More Analysis and Commentary STEVEN GROSSMAN 12/2/22 Analysis and Commentary STEVEN GROSSMAN 12/2/22 FDA and Continuing Resolutions: Everything You Need to Know Read More Advocacy at a Glance STEVEN GROSSMAN 12/2/22 Advocacy at a Glance STEVEN GROSSMAN 12/2/22 Reagan-Udall Report Upcoming; FY23 Approps Yet to be Determined Read More Analysis and Commentary STEVEN GROSSMAN 11/18/22 Analysis and Commentary STEVEN GROSSMAN 11/18/22 The F in FDA: Part 3 Read More Advocacy at a Glance STEVEN GROSSMAN 11/18/22 Advocacy at a Glance STEVEN GROSSMAN 11/18/22 2022 Election Results and Committee Leadership; CR Expectations Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 2/3/23 Analysis and Commentary STEVEN GROSSMAN 2/3/23 The President’s FY24 Budget Request and the Appropriations Cycle Read More
Advocacy at a Glance STEVEN GROSSMAN 2/3/23 Advocacy at a Glance STEVEN GROSSMAN 2/3/23 FDA Proposes to Reorganize Food Safety; More Details Coming Read More
Analysis and Commentary STEVEN GROSSMAN 1/27/23 Analysis and Commentary STEVEN GROSSMAN 1/27/23 What the Alliance Told the Commissioner About Food Safety Read More
Advocacy at a Glance STEVEN GROSSMAN 1/27/23 Advocacy at a Glance STEVEN GROSSMAN 1/27/23 Upcoming: Fireside Chat with Dr. Robert Califf Read More
Analysis and Commentary STEVEN GROSSMAN 1/20/23 Analysis and Commentary STEVEN GROSSMAN 1/20/23 What is the Latest in FDA Policy, Legislation, and International Affairs? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/20/23 Advocacy at a Glance STEVEN GROSSMAN 1/20/23 Harris to Chair House Ag/FDA Subcommittee Read More
Analysis and Commentary STEVEN GROSSMAN 1/13/23 Analysis and Commentary STEVEN GROSSMAN 1/13/23 A Separate Food Agency? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/13/23 Advocacy at a Glance STEVEN GROSSMAN 1/13/23 Appropriations, Debt Ceiling Uncertain Read More
Analysis and Commentary STEVEN GROSSMAN 1/6/23 Analysis and Commentary STEVEN GROSSMAN 1/6/23 The Alliance Believes in FDA Exceptionalism, You Should Too. Read More
Advocacy at a Glance STEVEN GROSSMAN 1/6/23 Advocacy at a Glance STEVEN GROSSMAN 1/6/23 Battle for Speaker has Implications for Appropriations Read More
Advocacy at a Glance STEVEN GROSSMAN 12/23/22 Advocacy at a Glance STEVEN GROSSMAN 12/23/22 Alliance thanks Appropriators for FY23’ Plans for FY24 Read More
Analysis and Commentary STEVEN GROSSMAN 12/23/22 Analysis and Commentary STEVEN GROSSMAN 12/23/22 Q&A on FDA’s FY23 Appropriation (let us know if you have other questions) Read More
Analysis and Commentary STEVEN GROSSMAN 12/16/22 Analysis and Commentary STEVEN GROSSMAN 12/16/22 FDA Benefits If You Join the Alliance for a Stronger FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 12/16/22 Advocacy at a Glance STEVEN GROSSMAN 12/16/22 One Week CR; FY23 Approps Looks Hopeful; Elections Complete Read More
Analysis and Commentary STEVEN GROSSMAN 12/9/22 Analysis and Commentary STEVEN GROSSMAN 12/9/22 Webinar with Valerie Jensen, Associate Director of FDA’s Drug Shortage Staff Read More
Advocacy at a Glance STEVEN GROSSMAN 12/9/22 Advocacy at a Glance STEVEN GROSSMAN 12/9/22 Warnock Reelected; FY23 Approps at an Impasse; Response to Reagan-Udall Foundation’s Report Read More
Analysis and Commentary STEVEN GROSSMAN 12/2/22 Analysis and Commentary STEVEN GROSSMAN 12/2/22 FDA and Continuing Resolutions: Everything You Need to Know Read More
Advocacy at a Glance STEVEN GROSSMAN 12/2/22 Advocacy at a Glance STEVEN GROSSMAN 12/2/22 Reagan-Udall Report Upcoming; FY23 Approps Yet to be Determined Read More
Analysis and Commentary STEVEN GROSSMAN 11/18/22 Analysis and Commentary STEVEN GROSSMAN 11/18/22 The F in FDA: Part 3 Read More
Advocacy at a Glance STEVEN GROSSMAN 11/18/22 Advocacy at a Glance STEVEN GROSSMAN 11/18/22 2022 Election Results and Committee Leadership; CR Expectations Read More
